Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.

Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva. 

Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.